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Resveratrol is a polyphenol that plays a potentially important role in many disorders and
has been studied in different diseases. The research on this chemical started through the
“French paradox,” which describes improved cardiovascular outcomes despite a high-fat
diet in French people. Since then, resveratrol has been broadly studied and shown to have
antioxidant, anti-inflammatory, anti-proliferative, and anti-angiogenic effects, with those on
oxidative stress possibly being most important and underlying some of the others, but
many signaling pathways are among the molecular targets of resveratrol. In concert they
may be beneficial in many disorders, particularly in diseases where oxidative stress plays
an important role. The main focus of this review will be the pathways affected by resvera-
trol. Based on these mechanistic considerations, the involvement of resveratrol especially
in cardiovascular diseases, cancer, neurodegenerative diseases, and possibly in longevity
will be is addressed.
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INTRODUCTION
The “French paradox” is a term that was generated in 1992 based
on epidemiological data from French people who had a low inci-
dence of coronary heart diseases (CHD) despite the consumption
of a diet in high saturated fat. This prompted researchers to
think about a possible reason, and led Renaud and de Lorgeril
(1992) to propose that moderate wine consumption (almost 57%
of the overall alcoholic drink consumption in France) explained
this apparent discrepancy, and further suggesting that a decrease
in platelet aggregation may be the main factor of the effect on
CHD. In an investigation by the World Health Organization, the
ratio of CHD-related mortality was found to be two- to three-
fold lower in France compared to other countries such as the
USA, UK, and Sweden (World Health Organization, 2009). Addi-
tionally, a study was carried out in Copenhagen with 6051 men
and 7234 women aged 30–70 years. In this study, low to moderate
wine intake was associated with lower mortality from cardiovas-
cular and cerebrovascular diseases (Gronbaek et al., 2001). After
these observations, a great deal of attention has been paid to the
French paradox and thousands of studies have been performed on
different aspects.
The French paradox has evolved considerably since 1992. Sev-
eral studies indicate that heavy wine drinkers may have almost the
same mortality rate due to CHD. Heavy alcohol consumption also
increases the prevalence of myocardial infarction, cardiomyopa-
thy, cardiac arrhythmias, hypertension, hemorrhagic shock, and
sudden death (Djousse et al., 2002; Lucas et al., 2005), confirming
that heavy alcohol consumption is harmful to the cardiovascular
system. However, the correlation of the drinking patterns with a
higher cardiovascular risk apparently depends on the type of drink
(van de Wiel and de Lange, 2008).
Many compounds have been identified to be specifically abun-
dant in red wine and many of these have a phenolic structure.
The main compounds in red wine (Waterhouse, 2002) include
flavonols such as myricetin, kaempferol, and the predominant
quercetin, the flavan-3-ol monomers catechin and epicatechin,
the oligomeric, and polymeric flavan-3-ols, or proanthocyanidins,
anthocyanins, phenolic acids including gallic acid, caftaric acid,
caffeic acid, p-coumaric acid, and the stilbene resveratrol. Thus,
red wine appears to be the richest source of resveratrol through
the skins, seeds, and stems of the grapes that are used.
RESVERATROL
Resveratrol is a stilbenoid named trans-3,4′,5,-trihydroxystilbene
and consists of two aromatic rings which are attached by a meth-
ylene bridge. It is a natural phenol and phytoalexin, produced
naturally by 72 different plant species especially grapevines, pines,
and legumes (Soleas et al., 1997). It is also present in peanuts,
soy beans, and pomegranates in high concentrations. In particular
Botrytis cinerea infection in grapes leads to the exclusive synthesis
of resveratrol in the leaf epidermis and grape skins. Since grape
skins are not fermented during white wine production, only red
wines contain noticeable amounts of resveratrol. This compound
was first mentioned by M. Takaoka in 1939 after its isolation from
the root of the white hellebore, Veratrum grandiflorum. The name
resveratrol was derived from this source since it is a resorcinol
derivative from a Veratrum species (Lancon et al., 2007).
Resveratrol is present in cis/trans isoforms both of which may
be glucosylated and the major trans isomer is the biologically
active one. Resveratrol is also produced by chemical (Farina et al.,
2006) and biotechnological (Trantas et al., 2009) synthesis and sold
as a nutritional supplement following its derivation from Japan-
ese knotweed which is the Itadori plant (Polygonum cuspidatum;
Kimura et al., 1985).
Resveratrol was identified to be converted to its monohy-
droxylated form, piceatannol, by the cytochrome P450 enzyme
CYP1B1 (Potter et al., 2002). Piceatannol possesses stronger
antitumor effects than resveratrol itself, and its hydroxyl group
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was shown to increase its inhibitory activity on protein kinases
(Thakkar et al., 1993) and nuclear factor kappa B (NFκB; Ashikawa
et al., 2002) and its inducer activity on apoptosis (Wieder et al.,
2001). Also the actions of resveratrol were found to be related
to its 3-O-sulfate (predominantly) and 3-O-beta-d-, 4′-O-beta-
d-glucuronide metabolites (Kaldas et al., 2003). Resveratrol was
found to be metabolized mainly to its glucuronide metabolite in
the rat small intestine used as a model (Lancon et al., 2004). How-
ever, in human plasma resveratrol sulfate was found to be the
major metabolite upon oral ingestion of resveratrol (Walle et al.,
2004). This sulfation is thought to be the main limiting factor
for the bioavailability of the compound. Sulfates were also found
to be the predominant resveratrol metabolites in Caco-2 human
colon carcinoma cells but this formation could be inhibited by
resveratrol itself (Maier-Salamon et al., 2006). Sulfotransferase
1A1 is found to be responsible for the formation of 3-O-sulfates,
and these metabolites show reduced anticancer activity in human
breast cancer cells compared to resveratrol (Murias et al., 2008). In
order to reduce the fast metabolism of resveratrol the stability of
resveratrol can be improved by liposome-encapsulation (Coimbra
et al., 2011).
Resveratrol bioavailability is believed to be affected by the food
matrix. Human subjects were administered pure resveratrol, and
high amount of glucuronide metabolites were detected in the
plasma and urine. However, oral doses of grape juice also resulted
in glucuronide and sulfate conjugates in the human plasma and
urine (Meng et al., 2004). The presence of resveratrol glucosides in
grape juice following glycosylation suggests a lower bioavailabil-
ity compared to the pure resveratrol is due to the role of matrix
sugar. But the administration of polyphenols in different vehicles
(white wine, grape juice, and vegetable juice) did not show any
difference in terms of the absorption of total resveratrol (Gold-
berg et al., 2003). However, food matrix-related factors such as
proteins, carbohydrates, fiber, fat, alcohol have been suggested as
positive or negative modifiers of the absorption of polyphenols
(Azuma et al., 2002; Visioli et al., 2003). In a pharmacokinetic
study of resveratrol carried out with 11 healthy volunteers, resver-
atrol was found to be better absorbed from natural grape products
than from tablets, confirming the importance of the matrix to its
bioavailability (Ortuno et al., 2010).
Resveratrol is a multipurpose compound believed to be effective
in improving health and preventing or treating chronic diseases,
therefore it has been the focus of many animal and human stud-
ies (Figure 1). Its biological activities have been shown to depend
on its structural determinants including the number and position
of carboxyl groups, intramolecular hydrogen bonding, stereoiso-
mery, and the presence of double bond. Trans-stilbene compounds
which possess ortho-diphenoxyl or para-diphenoxyl functional-
ities having a 4′-hydroxyl group and double bond show high
chemopreventive activity (Ovesna and Horvathova-Kozics, 2005).
Coppa et al. (2011) synthesized resveratrol analog 4,4′-dihydroxy-
trans-stilbene with two hydroxyl groups in the 4 and 4′ position
to obtain a molecule more active than resveratrol; this analog was
more active than resveratrol in the inhibition of secretion of the
potent vasoconstrictor peptide, endothelin-1.
To increase the activity, several resveratrol analogs have
been synthesized. Researchers have investigated the structure-
activity relationship by changing the number and the position
FIGURE 1 | Physiological and pathological effects of resveratrol in the organisms. Resveratrol plays important roles in distinct processes and the
parameters of these effects are summarized.
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of hydroxyl groups (Szekeres et al., 2010). Increasing the number
of hydroxyl groups on the phenol rings was proved to inhibit the
growth of human tumor cells. Also, 3,3′,4′,5-tetrahydroxy-trans-
stilbene, 3,4,4′,5-tetrahydroxy-trans-stilbene and 3,3′,4,4′,5,5′-
hexahydroxy-trans-stilbene showed almost 7000-fold higher anti-
radical activity compared to resveratrol (Murias et al., 2004,
2005). A hydroxyl group at the meta position in another analog
3,5,3′,4′,5′-pentahydroxy-trans-stilbene was identified as crucial
for the inhibition of cell transformation (Lee et al., 2008). Hexa-
hydroxystilbene, M8, was identified as the most effective analog
in various tumor cell lines with its high free radical scavenging
and therefore antitumor and antimetastatic activities. Whether the
same structure-activity relationships apply to each of the effects of
resveratrol, remains to be elucidated.
AFFECTED MOLECULAR AND CELLULAR MECHANISMS ON
THE CARDIOVASCULAR CELLS
Many in vitro studies have been carried out to elucidate the mech-
anisms of the action of resveratrol. Oxidative damage and reactive
species (RS) are strongly implicated in the pathogenesis of cardio-
vascular diseases (Park et al., 1991; Repine, 1991; Ago et al., 2010;
Schiffrin, 2010). Free radicals include RS such as reactive oxygen
species (ROS) and reactive nitrogen species (RNS). RS can damage
cellular components such as proteins, lipids, carbohydrates, and
nucleic acids (Nordberg and Arner, 2001). Because of the role of
oxidative stress in cardiovascular diseases, a great deal of attention
has been focused on natural antioxidants in the treatments.
The main ROS implicated in cardiovascular diseases are super-
oxide (O•−2 ), hydroxyl (OH•), and hydrogen peroxide (H2O2) and
the RNS are nitric oxide (NO) and peroxynitrite. While superoxide
and hydroxyl radicals are more reactive, hydrogen peroxide is more
membrane permeable. Concerning the basic mechanism, these
oxygen species are converted to each other by several mechanisms.
O•−2 is dismutated non-enzymatically or enzymatically by super-
oxide dismutase (SOD) to H2O2. Also various enzymes located
in the plasma membrane, the cytosol, peroxisomes, and mito-
chondria catalyze ROS formation. Resveratrol seems to increase
vascular oxidative stress resistance by scavenging H2O2 and pre-
venting oxidative stress-induced endothelial cell death and it has
been proposed that the antioxidant and anti-apoptotic effects of
resveratrol are responsible, at least in part, for its cardioprotective
effects (Ungvari et al., 2007). Resveratrol can also inhibit the formyl
methionyl leucyl phenylalamine (fMLP) induced production of
ROS from monocytes correlated with significant inhibitory effects
on fMLP-induced phosphatidylinositol 3-kinase (PI3K) activity
and Akt phosphorylation (Poolman et al., 2005). It was shown
that resveratrol attenuates increase in ROS induced by oxidized
low density lipoproteins (oxLDL) and H2O2 levels in bovine aortic
smooth muscle cells (Liu and Liu, 2004).
Nitric oxide is one of the important RNS in the pathogenesis of
cardiovascular diseases. NO is classified as a free radical in terms
of its unpaired electron but since it is not able to initiate typical
damage reactions to biomolecules it is relatively a non-reactive
radical. NO is produced in vivo during the oxidation of one of the
terminal guanidino-nitrogen atoms of l-arginine (Palmer et al.,
1988) to l-citrulline catalyzed by NO synthase (NOS), in the pres-
ence of nicotinamide adenine dinucleotide phosphate (NADPH)
and O2 (Moncada et al., 1991; Griffith and Stuehr, 1995). It is pro-
duced by the endothelial NOS (eNOS) and is a key determinant
of cardiovascular homeostasis (in endothelial cells not in all cell
types). Of note, low concentrations of NO are considered to be
beneficial in the cardiovascular system, e.g., by causing vasodilata-
tion, and only high concentrations are thought to have negative
effects due to reactive properties. Incubation of human umbilical
vein endothelial cells (HUVEC) and HUVEC-derived EA.hy 926
cells with resveratrol upregulated the expression of eNOS mRNA.
The expression of eNOS protein and the production of eNOS-
derived NO were also increased after long-term incubation with
resveratrol. This stimulation of eNOS expression and activity may
contribute to the cardiovascular protective effects attributed to
resveratrol (Wallerath et al., 2002). A significant decrease in intra-
cellular NO level and superoxide overproduction was found in
HUVEC treated with oxLDL, but not with LDL; this redox imbal-
ance was prevented by the addition of quercetin or resveratrol
(Kostyuk et al., 2011).
Resveratrol, with the aromatic groups in its structure, is
able to function as antioxidant and prevent oxidation reac-
tions. Resveratrol has been shown to have capacity to sequester
2,2-azinobis(3-ethylbenzthiazoline-6-sulfonic acid; ABTS), 1,1-
diphenyl-2-picrylhydrazyl (DPPH), and to scavenge hydroxyl rad-
ical (Soares et al., 2003). With its antioxidant capacity, resveratrol
was shown to delay oxidative stress related apoptosis in several cell
types including peripheral blood mononuclear cells, human reti-
nal pigment epithelium cells, rat pheochromacytoma cells, and
mouse 3T3 fibroblasts (Jang and Surh, 2001; Losa, 2003; Kutuk
et al., 2004). The antioxidative property of resveratrol could make
this compound protective in atherosclerosis since LDL oxidation
is an important process in this disease. In vitro results showed that
resveratrol inhibits copper and 2,2′-azobis (2-amidinopropane)
dihydrochloride (AAPH) induced LDL oxidation (Belguendouz
et al., 1997; Fremont et al., 1999). Blood platelets may also gen-
erate ROS at the site of atherosclerotic lesion, and resveratrol was
shown to inhibit this ROS production and decrease the degree
of lipid peroxidation (Olas and Wachowicz, 2002). The results of
Miura et al. (2000) suggested that resveratrol exerts its scaveng-
ing activity of lipid peroxidation via lipid peroxyl and/or carbon
centered radicals. On the other hand, resveratrol at low concentra-
tions, was shown to elicit a pro-oxidant property by an increase in
intracellular superoxide production (Ahmad et al., 2003). It was
also a pro-oxidant in the presence of copper ions (Ahmad et al.,
2005).
Resveratrol has been shown to be cardioprotective in many
conditions (Figure 2; Gresele et al., 2011). Cardiac fibroblasts reg-
ulate myocardial remodeling by proliferating, differentiating, and
secreting extracellular matrix proteins. Prolonged activation of
cardiac fibroblasts leads to cardiac fibrosis and reduced myocar-
dial contractile function. Resveratrol was tested on the growth and
proliferation of cardiac fibroblasts and their differentiation to the
hypersecretory myofibroblast phenotype. Cardiac fibroblasts pre-
treated with resveratrol showed inhibition of basal and angiotensin
(ANG) II-induced extracellular signal-regulated kinase (ERK) 1/2
and ERK kinase activation. This inhibition reduced basal prolif-
eration and blocked ANG II-induced growth and proliferation
of cardiac fibroblasts (Olson et al., 2005). Cardiac troponin, a
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FIGURE 2 |The effects of resveratrol on atherosclerosis process.
Resveratrol (R) prevents the ROS formation directly or by the inhibition of
NADPH oxidase, induces eNOS activity, inhibits monocyte
chemoattractant protein-1 (MCP-1) expression, inhibits the tumor necrosis
factor alpha (TNFα), and angiotensin II (AngII) induced endothelial cell
apoptosis.
heterotrimeric protein complex that regulates heart contraction,
represents an attractive target for the development of drugs for
treating heart disease. Resveratrol was identified as modulating
troponin C–troponin I interactions (Pineda-Sanabria et al., 2011).
Atherosclerosis is a wide ranging cardiovascular disease and is
characterized by the proliferation of certain cell types within the
arterial wall. This proliferation results from the accumulation of
cholesterol and triglyceride carrying plasma lipoproteins in the
arteries (Stocker and Keaney, 2004). In the disease process, phago-
cytic monocytes are transformed into macrophage foam cells
following penetration into the subendothelial space. Oxidatively
modified lipoproteins are endocytosed by a receptor-mediated
mechanism and these foam cells appear to be loaded with lipid
droplets rich in cholesteryl esters (Osterud and Bjorklid, 2003;
Schmitz and Grandl, 2007). CD36 takes the most important place
among the receptors responsible for the uptake of lipoproteins
(Stocker and Keaney, 2004; Schmitz and Grandl, 2007). Foam cells
are formed due to an accumulation of lipoproteins in macrophages
and smooth muscle cells. Thus visible lesions in the pathogenesis
of atherosclerosis originate mainly from foam cells and from an
adaptive thickening of the intima (Steinberg, 2009).
Resveratrol significantly affected the proliferation and the
shape of bovine pulmonary artery endothelial cells; growth was
suppressed and cells became elongated. The cellular phenotype
induced by resveratrol was dependent on intracellular calcium
and tyrosine kinase activities, and on the assembly of actin micro-
filaments and microtubules, but was unrelated to protein kinase
C activity. Resveratrol treatment also resulted in an increase
in phosphorylated ERK1/2 and NOS expression (Bruder et al.,
2001). Resveratrol inhibited the proliferation of pulmonary artery
endothelial cells, which, based on a flow cytometric analysis, cor-
relates with the suppression of cell progression through the S and
G2 phases of the cell cycle (Hsieh et al., 1999).
Lipid peroxidation and LDL oxidation are the early events in
atherosclerotic lesion formation (Salvayre et al., 2002; Vogiatzi
et al., 2009). The source of ROS formation in the vessel wall
are thought to be mostly macrophages but also other cells like
endothelial, smooth muscle, and adventitial cells produce RS in the
vessel wall (Fortuno et al., 2005). In addition, polymorphonuclear
leukocytes (PMN) are thought to contribute to the pathogenesis of
acute CHD together with the RS production. Resveratrol exerted a
strong inhibitory effect on ROS produced by PMN stimulated with
fMLP and the results obtained from this study indicated that trans-
resveratrol interferes with the release of inflammatory media-
tors by activating PMN and down-regulating adhesion-dependent
thrombogenic PMN functions (Rotondo et al., 1998).
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Hypercholesterolemia is a major risk for coronary artery dis-
eases and ROS have also been implicated in the development of
hypercholesterolemic atherosclerosis (Stokes et al., 2002). Patients
with elevated cholesterol may have increased susceptibility to
Alzheimer’s disease in addition to coronary artery disease and
hypertension (Pappolla et al., 2003) and amyloid beta formation
is known to be induced by cholesterol. In relation to its effect
on cholesterol homeostasis, resveratrol also enhances the choles-
terol efflux mediated by apolipoprotein A1 (apoA-1) up-regulating
the ATP binding cassette transporter A1 (ABCA-1) receptors,
and reducing cholesterol influx or uptake in J774 macrophages
(Berrougui et al., 2009).
Key components in atherogenesis are known to be increased
by RS in the vascular endothelium. They include signaling mole-
cules such as redox sensitive transcription factor NFκB activation
and adhesion molecules such as selectins, vascular cell adhesion
molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-
1), and chemokines such as monocyte chemoattractant protein-1
(MCP-1). Expression of adhesion molecules and MCP-1 are also
key steps for the monocyte adhesion and migration to form
macrophages and foam cells. Macrophage colony-stimulating fac-
tor (M-CSF) is an important factor regulating the survival, pro-
liferation, differentiation, and chemotaxis of macrophages (Fan
and Watanabe, 2003; Pixley and Stanley, 2004; Chitu and Stan-
ley, 2006; Harizi and Gualde, 2006). Several studies have been
carried out with endothelial cells. Resveratrol is known to be a tyro-
sine kinase inhibitor like other members of the tyrphostin family
and at concentrations as low as 1µM and 100 nM, it significantly
inhibits ICAM-1 and VCAM-1 expression by tumor necrosis fac-
tor α (TNF)-stimulated HUVECs and lipopolysaccharide (LPS)-
stimulated human saphenous vein endothelial cells (HSVEC),
respectively. Resveratrol also significantly inhibited the adhesion of
neutrophils to TNF-α-stimulated NIH/3T3 ICAM-1-transfected
cells (Ferrero et al., 1998).
Vascular smooth muscle cells (VSMC) have an important
role in vessel formation and therefore in the development and
progression of cardiovascular diseases. Vitisin B, a resveratrol
tetramer was shown to inhibit basal and platelet derived growth
factor-induced VSMC migration. Strikingly, it did not inhibit
VSMC proliferation but in contrast enhanced cell-cycle progres-
sion (Ong et al., 2011). In addition resveratrol was shown to
inhibit VSMC proliferation through a block on G1-S phase and
by an increase in apoptosis (Poussier et al., 2005). The effect
of resveratrol on early signaling cascades in rat aortic VSMCs
triggered by ANG II and epidermal growth factor (EGF) was inves-
tigated and the results showed that resveratrol does not influence
ANG II-mediated transactivation of EGF-receptor but potently
inhibits EGF-induced phosphorylation of Akt kinase, suggesting
that resveratrol acts downstream of EGF-receptor transactivation
in VSMCs (Haider et al., 2005). However, several other mech-
anisms are thought to be involved in the smooth muscle cell
response. Resveratrol was tested on cultured human aortic smooth
muscle cells (HASMC) in terms of growth and specific gene
responses. Suppression of HASMC proliferation by resveratrol was
accompanied by a dose-dependent increase in the expression of
tumor suppressor gene p53 and heat shock protein HSP27 (Wang
et al., 2006).
Platelets are centrally important in homeostasis and pathologi-
cal conditions such as thrombosis, atherosclerosis, and inflamma-
tion and are therefore key targets in the treatment of cardiovascular
disease. Thrombosis is the formation of a thrombus within the
blood vessel resulting in occlusion of blood flow. It is a major prob-
lem that triggers both myocardial infarction and stroke. Targeting
platelet aggregation using anti-platelet therapies is recognized as
effective in the treatment and prevention of cardiovascular disease.
Resveratrol, significantly inhibited collagen-, thrombin-,and ADP-
induced aggregation of platelets from healthy subjects. Hypercho-
lesterolemia induced by a high-cholesterol diet enhanced ADP-
induced platelet aggregation; resveratrol inhibited this platelet
aggregation induced by ADP in vivo in the absence of changes
in serum lipid levels (Wang et al., 2002). Also polyphenolic grape
extract induced a dose-dependent inhibition of trial to reduce
alloimmunization to platelets (TRAP)-induced and ADP-induced
platelet aggregation and Ca2+ mobilization; this inhibition was
accompanied by activation of platelet endothelial cell adhesion
molecule-1 (PECAM-1; de Lange et al., 2007).
THE EFFECTS OF RESVERATROL IN ANIMAL MODELS OF
CARDIOVASCULAR DISEASES
Supplemental resveratrol was shown to positively modify car-
diovascular risk factors including body mass index, cholesterol,
glucose tolerance, and systolic pressure in the Yorkshire swine
hypercholesterolemic model (Robich et al., 2010).
In the rat ischemia and ischemia-reperfusion model, resveratrol
showed protective effects against ischemia-reperfusion-induced
arrhythmias and mortality. Resveratrol pretreatment both reduced
the incidence and duration of ventricular tachycardia and ventric-
ular fibrillation. During the same period, resveratrol pretreatment
also increased NO and decreased lactate dehydrogenase levels in
the carotid blood (Hung et al., 2000).
Wang et al. (2005b) determined whether resveratrol has
alcohol-independent effects, and the size, density, and mean area
of atherosclerotic plaques, and thickness of the intima layer were
significantly reduced in hypercholesterolemic rabbits given deal-
coholized red wine, red wine, or resveratrol. Collagens (COL1A,
COL3A), lipoprotein lipase (LPL), and fatty-acid binding proteins
(FABPs) involved in cardiovascular diseases and lipid metabolisms
were upregulated by a high-fat diet and downregulated by resver-
atrol. Reverse transcriptase polymerase chain reaction confirmed
that resveratrol and resveratrol-containing grape extract prevented
the induction of FABP4 in peripheral blood mononuclear cells in
female pigs fed a high-fat diet (Azorin-Ortuno et al., 2012).
Hypocholesterolemic properties of resveratrol in apo E(−/−)
mice were investigated. The concentration of total-cholesterol
(total-C) and LDL-cholesterol (LDL-C) in plasma was signifi-
cantly lower in the resveratrol-supplemented groups compared to
the control group. Plasma paraoxonase (PON) activity was signif-
icantly higher in the resveratrol group. The hepatic hydroxymetyl-
glutaryl CoA (HMG-CoA) reductase activity was significantly
lower in resveratrol group than in the control group. Resveratrol
supplementation attenuated the presence of atherosclerotic lesions
and periarterial fat deposition in the apo E(−/−) mice. The pres-
ence of ICAM-1 and VCAM-1 in atherosclerotic vessels was dimin-
ished in the resveratrol-supplemented apo E(−/−) mice (Do et al.,
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2008). Moderate consumption of red wine was shown to improve
blood flow recovery by 32% after hindlimb ischemia in hyperc-
holesterolemic ApoE-deficient mice. The number of endothelial
progenitor cells, have an important role in postnatal neovascular-
ization, was found as increased by 60% in ApoE mice exposed to
red wine. Moreover, the migratory capacity of endothelial prog-
enitor cells was significantly improved in red wine-drinking mice
(Lefevre et al., 2007). The effect of resveratrol on the atherothrom-
botic tendency was assessed in apoE(−/−)/LDLR(−/−) mice and
the formation of atheroma in the aorta and the size of laser-
induced thrombus that mostly consisted of platelet aggregates was
significantly reduced in the resveratrol fed group (Fukao et al.,
2004).
Resveratrol was shown to significantly reduce infarct size com-
pared with control in wild-type mouse hearts and this protection
was shown through activation of the newly discovered survivor
activating factor enhancement (SAFE) prosurvival signaling path-
way that involves the activation of TNFα and the signal transducer
and activator of transcription 3 (STAT3; Lamont et al., 2011).
CLINICAL DATA ON CARDIOVASCULAR DISEASES
Several different approaches have been proposed for the treat-
ment of cardiovascular diseases. Understanding the mechanisms
underlying these diseases is necessary to develop therapeutic inter-
ventions. Several epidemiologic studies tested the relationship
between wine consumption and cardiovascular risk in order to
investigate the effects of resveratrol. Low to moderate wine intake
was shown to decrease the risk of death from cardiovascular
diseases in a study involving almost 25,000 Danish subjects (Gron-
baek et al., 1995). Another large population-based cohort study
compared light to moderate wine drinkers to non-drinkers and
reported that drinkers had less risk of death from all causes (Gron-
baek et al., 2000). Renaud et al. (1999) showed that mortality from
all causes was reduced by moderate wine consumption in 36,250
French middle-aged men, in an 18 years study. In 1,28,934 adults
from Northern California, followed for 20 years, light to moderate
wine intake decreased the risk of mortality from CHD (Klatsky
et al., 2003). However, heavy drinking caused a high risk of mor-
tality from non-cardiovascular reasons. Thun et al. carried out a
large prospective study and observed the long-term effect of alco-
hol consumption in 4,90,000 men and women. The cardiovascular
risk was 40% lower in men and women who had at least one drink
daily (Thun et al., 1997). In addition acute intake of dealcoholized
red wine was documented to improve endothelial function such
as decrease in arterial stiffness in a number of studies (Karatzi
et al., 2005). Also alcohol-free red wine decreased adverse effects
of smoking on systolic blood pressure (Papamichael et al., 2006).
250–500 ml of acute dealcoholized red wine intake was found to
improve brachial artery flow-mediated vasodilation (Agewall et al.,
2000; Hashimoto et al., 2001).
As the main compound in red wine, resveratrol alone was
also tested in the clinic. In 1997s, clinical trials were at the
beginning and therefore the effects of long-term resveratrol sup-
plementation was not known (Gehm et al., 1997). However,
recent studies did not show any important side effect in the
human trials (Boocock et al., 2007). Also recent clinical trials
have observed resveratrol to be safe and well-tolerated at doses
of up to 5 g/day. But the future possible side effects may bring
limitations for these doses. When searched in the website of clin-
ical trials (http://clinicaltrials.gov/ct2/results?term=resveratrol),
totally 20 studies come up and only 5 of them are com-
pleted. These trials include the patients of cardiovascular diseases,
type 2 diabetes, obesity, Alzheimer’s disease, and cancer. Some
studies also tested the pharmacokinetic properties of resvera-
trol. A summary of published clinical trials can be found in
Table 1.
LONGEVITY
Resveratrol is believed to be good for increasing the lifespan and
also for healthy aging. There are a lot of studies which tested the
role of resveratrol in aging. Most interesting results came out from
the lifespan studies in fruit flies and nematodes (Howitz et al.,
2003; Bass et al., 2007). In 2003, Howitz and Sinclair showed that
resveratrol extends the lifespan of Saccharomyces cerevisiae sig-
nificantly (Howitz et al., 2003). Later the role of resveratrol on
the lifespan of the worm Caenorhabditis elegans and the fruit
fly Drosophila melanogaster was reported (Wood et al., 2004).
Gruber et al. (2007) also showed that resveratrol has a posi-
tive effect on the lifespan of C. elegans. Furthermore resveratrol
was observed to extend the lifespan of a short-lived fish Notho-
branchius furzeri (Valenzano et al., 2006). In these organisms,
lifespan extension depends on Sir2, a conserved deacetylase, and
Sir2 underlies the beneficial effects of caloric restriction. Resver-
atrol produces changes associated with longer lifespan, including
increased insulin sensitivity, reduced insulin-like growth factor-1
(IGF-I) levels, increased AMP-activated protein kinase (AMPK),
and peroxisome proliferator-activated receptor-gamma coactiva-
tor 1α (PGC-1α) activity, increased mitochondrial number, and
improved motor function (Baur et al., 2006). On the other hand,
resveratrol treatment had only beneficial effects on elderly mice
and did not increase the lifespan when started to be given in midlife
(Pearson et al., 2008).
Resveratrol is implicated in many pathways related to stress con-
ditions, diseases, and aging. Among them sirtuin (SIRT) pathway
acts on the cell cycle, DNA damage response, metabolism, apopto-
sis, and autophagy with its deacetylase activity (Satoh et al., 2010).
There are seven human SIRTs (SIRT1-7), and SIRT1 is implicated
in the downstream pathways of calorie restriction to reduce the
incidence of age-related diseases (Pacholec et al., 2010). Resvera-
trol is the most potent natural compound able to activate SIRT1
and the mechanism of resveratrol shows similar properties with
the calorie restriction. However the certain mechanism of resvera-
trol remains unclear. In a recent work by Park et al. (2012) resver-
atrol was shown to inhibit cAMP-degrading phosphodiesterases
and to increase NAD+ and activity of SIRT1.
Resveratrol was also shown to inhibit expression of the replica-
tive senescence marker INK4a in human dermal fibroblasts, and
microarray experiments showed that 47 of 19,000 genes were
differentially expressed. These included genes for growth, cell divi-
sion, cell signaling, apoptosis, and transcription. Genes involved
in Ras and ubiquitin pathways, Ras-GRF1, RAC3, and UBE2D3,
were downregulated. These changes suggest resveratrol might
alter SIRT-regulated downstream pathways, rather than SIRT
activity. Serum deprivation and high confluency caused nuclear
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Table 1 | Clinical data and trials of resveratrol-containing interventions (Patel et al., 2011).
Group Resveratrol dose and application route Results Reference
25,000 male and female Low-moderate wine intake Decrease in cardiovascular risk Gronbaek et al. (1995)
36,250 middle-aged men Moderate wine intake for 18 years Decrease in death from all causes Renaud et al. (1999)
1,28,934 adults Light-moderate wine intake for 20 years Decrease in death from
cardiovascular heart disease
Klatsky et al. (2003)
4,90,000 men and women Long-term alcohol consumption (one drink
daily)
Decrease in cardiovascular risk Thun et al. (1997)
Male and female colorectal
cancer patients
Caplets Modulation of enzyme systems
involved in carcinogen detoxification
Chow et al. (2010)
Healthy males and females Wine and fruit juice Pharmacokinetic and metabolic
profile has been tested
Urpi-Sarda et al. (2005), Vitaglione et al.
(2005), Ortuno et al. (2010), Goldberg
et al. (2003), Meng et al. (2004)
Healthy males and females Capsules Pharmacokinetic and metabolic
profile has been tested. No side
effects have been observed.
la Porte et al. (2010), Boocock et al.
(2007), Almeida et al. (2009), Nunes
et al. (2009), Kennedy et al. (2010)
translocation of the SIRT1-regulated transcription factor FOXO3a
(Stefani et al., 2007).
Diminished mitochondrial oxidative phosphorylation and aer-
obic capacity are associated with reduced longevity and resvera-
trol is known to have impact on these parameters. Treatment of
mice with resveratrol significantly increased their aerobic capac-
ity, as evidenced by their increased running time and consump-
tion of oxygen in muscle fibers. The effects of resveratrol were
associated with an induction of genes for oxidative phosphory-
lation and mitochondrial biogenesis and were largely explained
by a resveratrol-mediated decrease in PGC-1α acetylation and an
increase its activity. This mechanism is consistent with resver-
atrol as a known activator of the protein deacetylase, SIRT1,
and by the lack of effect of resveratrol in SIRT1(−/−) mouse
embryonic fibroblasts (Lagouge et al., 2006). In another study,
resveratrol was shown to inhibit the mitochondrial respiratory
chain through complexes I–III in the rat brain (Zini et al.,
1999).
RESVERATROL IN CANCER
Cancer is one of the most destructive diseases worldwide. In the
year 2000, cancer was suggested to be responsible for 12% of the
nearly 56 million deaths worldwide and it is expected that can-
cer rates will further increase by 50% to 15 million new cases in
the year 2020, mainly due to steadily aging populations in both
developed and developing countries (Stewart and Kleihues, 2003).
Medical literature is full of studies showing the role of polyphe-
nolic compounds and resveratrol in cancer, and resveratrol was
especially shown to have chemopreventive and chemotherapeutic
effects on different cancer types. Resveratrol may block carcino-
gen activation and increase detoxification via inhibition of phase
I and induction of phase II enzymes. It may modulate cell cycle
and induce apoptosis. Anti-angiogenic effects and suppression of
invasion and metastasis is another important aspect of resveratrol.
On the other hand, it may sensitize tumor cells for chemotherapy
with other agents (Kundu and Surh, 2008).
In this direction, resveratrol can influence important cellu-
lar and molecular mechanisms related to carcinogenesis such
as inhibition of key proteins in signal transduction pathways
such as mitogen-activated protein kinases, activator protein-1
(AP-1), and NFκB. It also affects cell-cycle regulation, apoptosis
(Fresco et al., 2006), cell differentiation and proliferation, immune
response, and chemical metabolism (Nichenametla et al., 2006;
Figure 3). In this direction, Jang et al. (1997) first demonstrated the
chemopreventive effects of resveratrol in multi-stage carcinogen-
esis (e.g., initiation, promotion, and progression also angiogenesis
and metastasis).
In this part of the review, the effect of resveratrol on cancer
will be described step by step including the effects on proliferation
and transformation of cancer cells, angiogenesis, and therefore
metastasis.
Apoptosis, a regulated form of cell death, is a complex process
involving active participation of affected cells in a self-destruction
cascade and inhibition of apoptosis leads to uncontrolled cell
proliferation, resulting in events related to autoimmune disor-
ders and cancer (Saikumar et al., 1999; Watson et al., 2000).
Apoptosis is conceivably the most potent defense against cancer.
Tumor cells can acquire resistance to apoptosis, for instance, by
over expressing anti-apoptotic proteins such as Bcl-2 or down-
regulate/mutate proapoptotic proteins such as Bax, the expres-
sion of both being regulated by the p53 tumor suppressor gene
(Miyashita et al., 1994; Wang, 1999). P53 is a transcription fac-
tor essential for the prevention of cancer formation and it can
be damaged by radiation, several chemicals, and viruses such as
the human papilloma virus. The p53 pathway is not efficient in
human cancer either by p53 gene mutation (60% of cancers) or by
loss of cell signaling upstream and downstream of p53 (Bourdon,
2007).
Since apoptosis provides a physiologic mechanism for elim-
inating abnormal cells, dietary factors affecting apoptosis can
present important effects on carcinogenesis. Conceivably, activa-
tion of apoptosis in pre-cancerous cells offers a prevention mech-
anism of cancer (chemoprevention) by dietary factors (Martin,
2006).
Subsequently, resveratrol has been shown to suppress prolifer-
ation of a wide variety of human tumor cells in vitro (Aggarwal
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FIGURE 3 | Resveratrol binds to integrin αvβ3 and activates ERK1/2
regulates cyclooxygenase-2 (COX-2) expression. COX-2 is associated with
small ubiquitin-related modifier 1 (SUMO-1), and phosphoERK1/2 translocates
to the nucleus where the complex binds to p53. In the nucleus, COX-2 is
sumoylated (S), p53 is phosphorylated (P) and acetylated (A). The COX-2 and
p53 complex binds to promoters of p53-responsive genes and initiates
transcription. Activation of ERK1/2 and cell proliferation can be promoted by
the binding of thyroid hormone and DHT each other to discrete sites on
integrin αvβ3. Estrogen (E2) binds to estrogen receptor (ER) which is the cell
surface receptor and integrin αvβ3 may assist in that process. Meanwhile,
resveratrol and non-peptide hormone play a distinct role on the activation of
ERK1/2 which differs from each other.
et al.,2004; Howells et al.,2007; Kundu and Surh,2008),which have
led to numerous pre-clinical animal studies to evaluate the cancer
chemopreventive and chemotherapeutic potential of resveratrol
(Bishayee, 2009). There is growing in vitro evidence demonstrat-
ing the inhibitory effects of resveratrol on liver cancer. Delmas
et al. (2000) showed that the proliferation of rat hepatoma and
human hepatoblastoma HepG2 cells were negatively impacted by
the addition of resveratrol to the culture medium and ethanol
potentiated the effects of resveratrol in both cell lines. These
results were attributed to the ability of resveratrol to prevent or
delay the cells from entering mitosis and increasing the num-
ber of cells arrested in the S and G2/M phase. Hepatic growth
factor (HGF) has largely been implicated in the ability of pri-
mary hepatic tumors to proliferate and invade adjacent tissue.
The effects of resveratrol on HGF-mediated invasion were deter-
mined in HepG2 cells, in part, to understand the mechanisms of
resveratrol’s anti-hepatocellular carcinoma property. Resveratrol
was found to decrease HGF-induced scattering and invasion of
liver cancer cells with concurrent inhibition of cell proliferation
possibly due to a post-receptor mechanism rather than apoptosis
(De Lédinghen et al., 2001).
Kuo et al. (2002) examined the anti-proliferative effects of
resveratrol in two human liver cancer cell lines, namely HepG2
and Hep3B. The results showed that resveratrol inhibited cell
growth only in p53-positive HepG2 cells, which was a result of
cellular apoptotic death via p53-dependent pathway. It was also
shown that resveratrol-treated cells were arrested in G1 phase
and were associated with an increase in p21 and Bax expression.
Michels et al. (2006) observed cytotoxic effect of resveratrol on rat
hepatoma cells due to induction of apoptosis via caspase activa-
tion. Overexpression of anti-apoptotic Bcl-2 has been associated
with elevated cyclooxygenase-2 (COX-2) expression (Tsujii and
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DuBois, 1995) and resveratrol was shown to suppress COX activ-
ity in the livers of mice treated with diethylnitrosamine (Khanduja
et al., 2004).
Resveratrol induces p53-independent, X-linked inhibitor of
apoptosis protein (XIAP)-mediated translocation of Bax to mito-
chondria where it undergoes oligomerization to initiate apop-
tosis. Resveratrol treatment promotes interaction between Bax
and XIAP in the cytosol and mitochondria, suggesting that XIAP
plays a critical role in the activation and translocation of Bax
to mitochondria. This process does not involve p53 but requires
accumulation of Bim and t-Bid in mitochondria. Bax primarily
undergoes homo-oligomerization in mitochondria and plays a
major role in release of cytochrome c to the cytosol. Bak, another
key protein, that regulates the mitochondrial membrane perme-
abilization, does not interact with p53 but continues to associate
with Bcl-xL. Thus, the proapoptotic function of Bak remains sup-
pressed during resveratrol-induced apoptosis. Caspase-9 silencing
inhibits resveratrol-induced caspase activation, whereas caspase-8
knockdown does not affect caspase activity, suggesting that resver-
atrol induces caspase-9-dependent apoptosis. These findings char-
acterize the molecular mechanisms of resveratrol-induced caspase
activation and subsequent apoptosis in cancer cells (Gogada et al.,
2011).
Resveratrol can positively regulate SIRT1 transcription and
activity, respectively. Increased SIRT1, in turn, inhibits expres-
sion and/or activity of several oncogenes, leading to reduced cell
proliferation, increased apoptosis, and tumor suppression (Deng,
2009).
Lin et al. demonstrated the existence of a plasma membrane
receptor for resveratrol near the arginine–glycine–aspartate recog-
nition site on integrin αvβ3 that is involved in stilbene-induced
apoptosis of cancer cells. Resveratrol treatment in vitro causes
activation and nuclear translocation of mitogen-activated pro-
tein kinase, consequent phosphorylation of Ser-15 of p53, and
apoptosis (Lin et al., 2011).
Resveratrol treatment of human glioblastoma cells was shown
to induce a delay in cell-cycle progression during S phase associated
with an increase in histone H2AX phosphorylation. Furthermore
it was able to inhibit the ability of recombinant human TOPO II
alpha to decatenate kDNA, so that it could be considered a TOPO
II poison (Jo et al., 2006; Leone et al., 2010).
Cyclooxygenase-2 is an enzyme which has been found to be
locally induced by proinflammatory mitogens, cytokines, and
growth factors during inflammation and carcinogenesis. COX-2
has been associated with cell proliferation, differentiation, apop-
tosis, angiogenesis, invasiveness, and metastasis – all of which
are involved in multi-stage tumorigenesis (Prescott and Fitz-
patrick, 2000). Treatment with resveratrol was shown to decrease
COX-2 expression in a concentration-dependent manner, suggest-
ing involvement of anti-inflammatory mechanisms. Overexpres-
sion of anti-apoptotic Bcl-2 has been associated with elevated
COX-2 expression (Tsujii and DuBois, 1995). Recently, it has
been shown that resveratrol binds to COX-2 directly to inhibit
its enzyme activity, suppresses COX-2-mediated PGE2 produc-
tion, and exerts antitumor effects on human colon adenocar-
cinoma cells in vitro and ex vivo. According to prior in vivo
studies, tumor-inhibitory effects of resveratrol in breast, esoph-
agus, intestine, and skin have been associated with its ability
to inhibit COX-2 (Bishayee, 2009). It was also found in the
same study that resveratrol can decrease the degradation of
IκB and the nuclear translocation of p65, indicating that this
dietary agent can suppress diethylnitrosamine-mediated NFκB
activation which is transcription factor for COX-2 in rat liver
carcinogenesis.
ERK1/2 and MAPK isoforms that are inducible components
of normal cellular signal transduction processes. Pathways of
ERK1/2 activation can be triggered by a variety of stimuli and have
been particularly well characterized in growth factor-stimulated
cells or in the setting of inflammation. ERK1/2 is directly acti-
vated by MAPK-kinase (MEK1/2). Upstream activators in the
MEK–MAPK pathway are Raf-1 kinase and, at the cell mem-
brane, Ras (Malarkey et al., 1995). Resveratrol activates MAPK
at low concentrations (1 pM to 10µM), but higher concentrations
(50–100µM) of resveratrol can inhibit this signal transducing
kinase in cancer cells (Miloso et al., 1999). It has been shown
that resveratrol induces ERK1/2 activation in prostate (Lin et al.,
2002; Shih et al., 2004), breast (Tang et al., 2006), glial (Lin et al.,
2008b), head, and neck cancer cells (Lin et al., 2008a). The bio-
chemical steps between formation of the COX-2-MAPK-ERK1/2
complex and activation of p53 in resveratrol-treated cells are now
clear (Lin et al., 2008a,b). In fact, recent studies have demon-
strated that posttranslational modification of COX-2 in the form
of tyrosine phosphorylation regulates COX-2 activity in cere-
bral endothelial cells (Parfenova et al., 1998). Resveratrol-induced
COX-2 associates with activated ERK1/2 in the nucleus of can-
cer cells (Lin et al., 2008a,b). Activated nuclear ERK1/2 has been
shown to form complexes with transcriptionally active proteins,
such as receptors for non-peptide hormones, signal transducing
and activator of transcription (STAT) proteins, and the oncogene
suppressor protein, p53 (Lin et al., 1999). Activated ERK1/2 in
this context serves phosphorylation of (activation) the associated
proteins.
Certain endogenous polypeptide growth factors, including
EGF, IGF, and fibroblast growth factor, have been implicated
in the development and progression of cancers (Djakiew, 2000;
Shih et al., 2004). These factors are capable of rapidly activating
ERK1/2 in several cell lines (Shih et al., 2004). EGF inhibits the
action of resveratrol on both ERK1/2 activation and the induc-
tion of apoptosis in both androgen-responsive and unresponsive
prostate cancer cells. These results suggest that increased ambi-
ent EGF levels would oppose any clinical actions that resveratrol
may have.
Additionally,on the cancer cell surface, resveratrol binds to inte-
grin αvβ3 and activates ERK1/2. In the same pathway, resveratrol
induces COX-2 expression is also regulated by ERK1/2. Following
the synthesis, COX-2 is associated with SUMO-1, and phospho-
ERK1/2 translocates to the nucleus where the complex binds to
p53. In the nucleus, COX-2 is sumoylated, p53 is phosphorylated
and acetylated. The COX-2 and p53 complex binds to promot-
ers of p53-responsive genes and initiates transcription. Activation
of ERK1/2 and cell proliferation can be promoted by binding
of thyroid hormone and dihydrotestesterone (DHT) each other
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to discrete sites on integrin αvβ3. Estrogen (E2) binds to estro-
gen receptor (ER) which is the cell surface receptor and integrin
αvβ3 may assist in that process. Meanwhile, resveratrol and non-
peptide hormones play a distinct role on the activation of ERK1/2
which differs from each other. For resveratrol-induced inhibition
of apoptosis, the activation of ERK1/2 via non-peptide hormones
is known to be critical. When EGF binds to EGF-receptor, ERK1/2
is activated and the activation of ERK1/2 by EGF directly inhibits
resveratrol-induced ERK1/2. Thus, the inhibitory role for resvera-
trol results in ERK1/2 downstream but EGF affects directly ERK1/2
activation (Lin et al., 2011; Figure 3).
On the other side, a significant amount of resveratrol accumu-
lates and is retained in the liver (Bertelli et al., 1998; Vitrac et al.,
2003; Abd El-Mohsen et al., 2006). Resveratrol has been shown
to inhibit the hepatic carcinogen-activating enzymes, includ-
ing cytochrome P450 1A1 (CYP1A1) and CYP3A/2 and induce
hepatic phase 2 conjugating enzymes, namely NAD(P)H:quinine
oxidoreductase, UDP-glucuronosyl-transferase, and glutathione
S-transferase (GST) in vitro and in vivo (Ciolino et al., 1998;
Canistro et al., 2009). The resultant effects of these enzyme mod-
ulations by resveratrol could be the reduced exposure of cells
to carcinogens due to inhibition of carcinogen activation and/or
elevated carcinogen detoxification and elimination. The most fas-
cinating property of resveratrol, with regards to liver cancer, is
its strong anti-inflammatory and antioxidant properties (Rubi-
olo et al., 2008), as both oxidative stress and inflammation have
been strongly implicated in the occurrence and progression of
hepatocellular carcinoma.
Resveratrol inhibited the development of preneoplastic lesions
in carcinogen-treated mouse mammary glands in culture and
inhibited tumorigenesis in a mouse skin cancer model (Jang et al.,
1997). Athymic mice have been used for the determination of
the role of resveratrol on human melanoma xenograft growth.
The results suggested that resveratrol may not be useful in the
treatment of melanoma and the effects of phytochemicals on cell
cultures may not translate to the whole animal system which is
thought to be because of the metabolization of resveratrol as will
be explained below (Niles et al., 2006).
The role and the potential mechanism(s) of resveratrol
were tested in N -nitrosomethylbenzylamine (NMBA)-induced
rat esophageal tumorigenesis in F344 male rats. The results sug-
gest that resveratrol suppressed NMBA-induced rat esophageal
tumorigenesis by targeting COXs and PGE2 (Li et al., 2002).
Antileukemic activity of resveratrol was examined in vitro and
in vivo using a mouse myeloid leukemia cell line (32Dp210).
Despite strong anti-proliferative and proapoptotic activities of
resveratrol against the cells in vitro, a potential antileukemia effect
occurs only in a small fraction of mice (Gao et al., 2002). Resver-
atrol was found to reduce the tumor volume, tumor weight, and
metastasis to the lung in mice bearing highly metastatic Lewis
lung carcinoma (LLC) tumors. The antitumor and antimetastatic
activities of resveratrol was suggested to be due to the inhibition
of DNA synthesis in LLC cells and the inhibition of LLC-induced
neovascularization and tube formation (angiogenesis) of HUVEC
by resveratrol (Kimura and Okuda, 2001).
Accumulating evidence suggests that combinations of two or
more compounds could be much more effective. Combinations of
several chemotherapeutic drugs also offer the possibility of low-
ering their doses and consequently may reduce unwanted adverse
effects. Resveratrol has been found to potentiate the effects of
chemotherapeutic agents and ionizing radiation (Cucciolla et al.,
2007). Angiogenesis is a critical issue for the progression and sever-
ity of cancer. Resveratrol exerts anti-angiogenic activity (Chen
et al., 2006; Garvin et al., 2006; Hu et al., 2007) and this activ-
ity has been related to the modulation of tumor cell release of
thrombospondin-1 (TSP1) and vascular endothelial growth factor
(VEGF). These effects lead to vascular endothelial cell apopto-
sis (Trapp et al., 2010). In human leukemia cells, secretion of
VEGF was shown to be inhibited by resveratrol (Tang et al., 2007).
Resveratrol inhibited pro-MMP-9 production at 25 or 50µM
concentrations in colon cancer cells (Kimura et al., 2008). Also
expression and activity of MMP-2 and MMP-9 were downreg-
ulated in MCF-7 cells, mouse mammary tumors, and multiple
myeloma cells (Banerjee et al., 2002; Sun et al., 2006; Tang et al.,
2008).
Considering these advantages, resveratrol may be used in
combination with other chemotherapeutic drugs and radia-
tion therapy to enhance their therapeutic efficacy while limiting
chemotherapy- and radiotherapy-associated negative side effects.
Additionally, it seems to be logical to extend this approach to
the field of chemoprevention, especially if one considers that
dietary chemopreventive agents are naturally present in the diet in
combination (Francy-Guilford and Pezzuto, 2008).
RESVERATROL IN NEURODEGENERATIVE AND OTHER
DISEASES
Resveratrol was claimed to be an ideal compound for the treat-
ment of neurodegenerative diseases (Anekonda, 2006). Resveratrol
was shown to diminish neurodegeneration related plaque for-
mation in a region specific manner. The largest reductions in
the percent area occupied by plaques were observed in medial
cortex (−48%), striatum (−89%), and hypothalamus (−90%;
Karuppagounder et al., 2009). Resveratrol was shown to signifi-
cantly prevent intracerebroventricular (ICV) streptozotocin (STZ)
induced cognitive impairment in rats (Sharma and Gupta, 2002).
3-Nitropropionic acid, an inhibitor of complex II of the electron
transport chain, causes Huntington’s disease-like symptoms in
rodents and resveratrol, with cyclooxygenase I inhibitory activ-
ity, significantly improved motor and cognitive impairment in
the 3-nitropropionic acid-induced model of Huntington’s dis-
ease. These results were correlated with its antioxidant activ-
ity (Kumar et al., 2006). Resveratrol was shown to protect the
spinal cord from secondary spinal cord injuries via improving
the energy metabolism system and inhibiting the lipid peroxi-
dation in the local injured spinal cord (Yang and Piao, 2003).
The effect of chronic treatment of resveratrol was evaluated
in focal ischemia induced by middle cerebral artery occlusion
in rats. Treatment prevented motor impairment, caused a rise
in levels of malondialdehyde (MDA) and reduced glutathione
and the volume of infarct as compared to control (Sinha et al.,
2002).
Hypercholesterolemia is a known risk factor for Alzheimer’s
disease, and oxidative stress may play an important role in the
progression of this disease. MDA levels as an indicator of oxidative
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stress in hypercholesterolemic rabbits were shown to be increased
consistent with the previous results (Ozer et al., 1998, 2006; Aytan
et al., 2008). Additionally, slight increase in 4-hydroxynonenal
(HNE)-proteins, 3-nitrotyrosinated proteins, and protein car-
bonyls were observed in hippocampus area of the rabbits. Resvera-
trol was effective to modulate multiple mechanisms in Alzheimer’s
disease and it was shown to lower the levels of secreted and intra-
cellular amyloid-β (Aβ) peptides produced from different cell
lines. Resveratrol was suggested to decrease Aβ amounts. It has
no effect on the Aβ-producing enzymes β- and γ-secretases, but
promote instead intracellular degradation of Aβ via a mechanism
that involves the proteasome which may be induced by oxidative
stress (Marambaud et al., 2005).
Regarding ischemic brain injury, resveratrol inhibited voltage-
activated potassium currents in rat hippocampal neurons (Gao
and Hu, 2005). In PC12 cells, Aβ induces the degradation of
cytoplasmic IκBα and increases the translocation of p65 to the
nucleus. These processes were reversed when the cells were treated
with resveratrol (25µM), suggesting that NFκB, in addition
to its upstream signal transduction, was affected by resveratrol
treatments (Jang and Surh, 2001).
Studies showed that resveratrol may be effective in diabetes.
It was shown to possess hypoglycemic and hypolipidemic effects
in STZ-induced type-1 diabetic rats by amelioration of common
symptoms, such as body weight loss, polyphagia, and polydip-
sia. Also glucose uptake by hepatocytes, adipocytes, and skeletal
muscle and hepatic glycogen synthesis were all stimulated by
resveratrol treatment (Su et al., 2006). Estradiol is known to mod-
ulate insulin sensitivity and, consequently, glucose homeostasis.
Insulin dependent and independent glucose uptake stimulation by
resveratrol is shown to be regulated by ER (Deng et al., 2008). In
STZ-nicotinamide-induced experimental type 1 diabetes in rats
resveratrol resulted in significant decrease in the levels of blood
glucose, glycosylated hemoglobin, blood urea, serum uric acid,
serum creatinine, and diminished activities of aspartate transami-
nase (AST), alanine transaminase (ALT), and alkaline phosphatase
(ALP). The antihyperglycemic nature of resveratrol is also evi-
denced from the improvement in the levels of plasma insulin
and hemoglobin (Palsamy and Subramanian, 2008). Diabetic
nephropathy is a serious microvascular complication and one of
the main causes of end-stage renal disease. Treatment with resvera-
trol significantly attenuated renal dysfunction and oxidative stress
in diabetic rats (Sharma et al., 2006). The effects of resveratrol
on memory and on acetylcholinesterase (AChE) activity in the
cerebral cortex, hippocampus, striatum, hypothalamus, cerebel-
lum, and blood in STZ-induced diabetic rats were tested. In this
study, resveratrol prevented the impairment of memory induced
by diabetes and the increase in AChE activity (Schmatz et al.,
2009). Insulin provides blood glucose homeostasis by the stim-
ulation of glucose uptake by translocation of glucose transporter
Glut-4 from intracellular pool to the caveolar membrane system.
Resveratrol-mediated Glut-4 translocation in the STZ-induced
diabetic myocardium was tested and resveratrol was shown to trig-
ger some of the similar intracellular insulin signaling components
in myocardium such as eNOS, Akt through AMPK pathway and
also by regulating the caveolin-1 and caveolin-3 status that might
play an essential role in Glut-4 translocation and glucose uptake
in STZ- induced type-1 diabetic myocardium (Penumathsa et al.,
2008).
In several studies, resveratrol has been shown to possess anti-
inflammatory effects since it plays role as aryl hydrocarbon recep-
tor antagonist and inducible COX-2 inhibitor. The effect of resver-
atrol was examined in a model of hyperalgesia induced by car-
rageenan in the rat. Pretreatment with resveratrol did not reverse
swelling and edema, but reversed the hyperalgesia induced by
local tissue injury provoked by carrageenan (Gentilli et al., 2001).
Resveratrol was found to inhibit NO generation, cytosolic iNOS
protein and steady-state mRNA levels in lipopolysaccaride (LPS)
activated RAW 264.7 macrophages. In electrophoretic mobility
shift assays, the activation of NFκB induced by LPS was inhib-
ited by resveratrol (Tsai et al., 1999). In a study carried out in
rabbits, arthritis was induced by intra-articular injection of LPS
into the knee joints. Resveratrol was shown to ameliorate the syn-
ovial inflammation after intra-articular injection (Elmali et al.,
2007).
Resveratrol adversely affects the critical early event in the her-
pes simplex virus types 1 and 2 (HSV-1 and HSV-2) replication
cycle, that has a compensatory cellular counterpart (Docherty
et al., 1999). Also topically applied resveratrol inhibits HSV
lesion formation in the skin of mice (Docherty et al., 2004).
Human cytomegalovirus replication was also inhibited by resver-
atrol via the blockage of virus-induced activation of the EGFR and
phosphatidylinositol-3-kinase signal transduction as well as NFκB
activation (Evers et al., 2004). Resveratrol was found to inhibit
varicella-zoster virus replication in a concentration-dependent
and reversible manner (Docherty et al., 2006). Resveratrol was
shown to synergistically enhance the anti-HIV-1 activity of the
nucleoside analogs zidovudine, zalcitabine, and didanosine by the
reduction of viral replication (Heredia et al., 2000).
ADMINISTRATION DOSES, ROUTES, AND BIOAVAILABILITY
OF RESVERATROL
Resveratrol synthesis in plants is catalyzed by resveratrol synthase
enzyme. In red wine, the levels are much higher than in white wine
because the skin of the grapes are removed during the fermenta-
tion of white wine (Gu et al., 1999). Also the levels in red wine
depend on the type of the grape. Besides wine, peanut is another
source of resveratrol (Wang et al., 2005a). Also mulberry is a source
and is sold as nutritional supplement (Stewart et al., 2003). Cocoa
and dark chocolate include low levels of resveratrol (Hurst et al.,
2008). And recently Japanese Knotweed has become popular for
its high content of a resveratrol analog, piceatannol (Piotrowska
et al., 2012).
Before clinical trials, researchers use in vitro results to be able
proceed. Choosing the right concentration is a crucial problem
for the in vitro studies. The tested concentration should reflect
the clinical usage and should be estimated according to the target
pathway. Generally used concentrations of resveratrol range from
µmol/l to mmol/l and observed metabolites are usually in nmol/l
concentrations. Elevated doses are sometimes used to force the
outcome but these results should be carefully interpreted (Scott
et al., 2012).
In vitro studies have used several different concentrations of
resveratrol according to the target of the study. Chao et al. (2010)
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showed that 0.1, 1, and 10µM resveratrol were neuroprotective in
SH-SY5Y cells as shown by lactic dehydrogenase release, caspase-3
activity, and also by JNK and mTOR pathway studies. In another
study in the same cell line, a 50µM concentration was shown
to reduce cellular death by inhibiting the activation of caspase
7 and the degradation of PARP (Nicolini et al., 2001). Further,
resveratrol at 171–342µg/ml concentrations was shown to be anti-
microbial against Staphylococcus aerius, Enterococcus faecalis, and
Pseudomonas aeruginosa (Chan, 2002).
For the cancer chemopreventative action of resveratrol, it
is important to know the pathway that is effective. Generally,
proliferation of the cells have been shown to be suppressed above
5µM resveratrol which may often be close to 100µM (Scott et al.,
2012). Resveratrol (52–74µM) was shown to antagonize the effect
of linoleic acid, a potent breast cancer cell stimulator, and sup-
pressed the growth of both ER-positive and -negative cell lines
((Damianaki et al., 2000; Nakagawa et al., 2001). 10–40µM were
shown to be enough to induce apoptosis in JB6 mouse epidermal
cells via JNK activation (She et al., 2002).
Regarding its cardioprotective role, NOS expression was shown
to increase at 1µM concentration while it was decreased at 60 nM
(Gu et al., 2006).
There are several routes of administration for resveratrol. Buc-
cal application is one way, this occurs by direct absorption through
mucous membrane of the mouth. However, the low solubility
of resveratrol limits the absorbable amount through the buc-
cal mucosa. Oral application as a pill restricts the bioavailability
because resveratrol is metabolized rapidly into glucuronate and
sulfonate conjugates in the intestine and liver (Walle et al., 2004).
Following oral administration in a dose of 25 mg, only trace
amounts of unchanged resveratrol (<5 ng/ml) were detected in
plasma. Although the systemic bioavailability of resveratrol is very
low, accumulation of resveratrol and potentially active resvera-
trol metabolites in epithelial cells along the aerodigestive tract
is thought to still produce cancer-preventive and other effects
(Walle et al., 2004). On this basis, SRT-501 and later SRT2104
and SRT2379 have been developed as different formulations of
resveratrol.
Several pharmacokinetic studies have been carried out to test
the bioavailability of resveratrol. In rat studies, trans-resveratrol
was found to be in different conjugates throughout the body and
its aglycone form was found to be the main metabolite retained in
the tissues (Marier et al., 2002; Wenzel et al., 2005; Abd El-Mohsen
et al., 2006). In another study, abundant trans-resveratrol-3-O-
glucuronide and trans-resveratrol-3-sulfate were identified in rat
urine, mouse serum, and in incubated rat and human hepatocytes
(Yu et al., 2002).
The steady-state pharmacokinetics and tolerability of trans-
resveratrol 2000 mg given twice daily with food, quercetin and
alcohol (ethanol) was tested in eight healthy subjects. This resulted
in adequate exposure and was well tolerated, although diarrhea
was frequently observed. In order to maximize the actions of
trans-resveratrol, it should be taken with a standard breakfast
and not with a high-fat meal. Furthermore, combined intake with
quercetin or alcohol did not influence trans-resveratrol efficiency
(la Porte et al., 2010).
A phase I study of oral resveratrol (single doses of 0.5, 1, 2.5,
or 5 g) was conducted in 10 healthy volunteers and consumption
of resveratrol at these levels did not cause serious adverse affects
(Boocock et al., 2007).
Chemopreventive parameters and metabolic conversion of
resveratrol were tested in vivo. Feeding of different dosages of
resveratrol revealed no effect on the different chemopreven-
tive parameters, and the formation of trans-resveratrol-3-sulfate,
trans-resveratrol-4′-sulfate, trans-resveratrol-3,5-disulfate, trans-
resveratrol-3,4′-disulfate, trans-resveratrol-3,4′,5-trisulfate, trans-
resveratrol-3-O-beta-d-glucuronide, and resveratrol aglycone was
detected by HPLC analysis, depending on the biological mate-
rial. The lack of effect of resveratrol on the chemopreventive
parameters is probably due to the formation of various con-
jugates reducing its bioavailability in the rat (Wenzel et al.,
2005).
CONCLUSION
The enormous amount of clinical and animal studies suggests that
resveratrol may have beneficial effects to improve health, prevent,
and/or treat chronic diseases in humans. However, despite a large
amount of circumstantial and experimental evidence, definitive
clinical studies are largely missing. Moreover, explaining the mole-
cular basis of the beneficial results of resveratrol still awaits further
detailed and extensive epidemiological studies. Further studies are
needed regarding the genetic factors that account for differences
in bioavailabity and physiological responses to resveratrol between
individuals. It should be clarified whether resveratrol can have
either synergistic or additive effects in combination with other
therapies.
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